Molecular Machines Inc is categorized under Commercial Biotechnical Research in Montclair, NJ and active since 1997.
Molecular Machines Inc was established in 1997, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Roger Cubicciotti at the company’s single location by writing to 258 Midland Avenue, Montclair, New Jersey NJ 07042 or by phoning (973) 746-3525. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Molecular Machines Inc |
| Contact Person: | Roger Cubicciotti |
| Address: | 258 Midland Avenue, Montclair, New Jersey 07042 |
| Phone Number: | (973) 746-3525 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 1997 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Molecular Machines Inc was started in 1997 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Roger Cubicciotti for inquiries that concern Molecular Machines Inc by calling the company number (973) 746-3525, as your correspondence is most welcome. Additionally, the physical location of the single location of Molecular Machines Inc can be found at the coordinates as well as the street address 258 Midland Avenue in Montclair, New Jersey 07042.
For its online presence, you may visit Molecular Machines Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.